LEXINGTON, Mass. / Mar 07, 2024 / Business Wire / Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced that it has formally notified The Nasdaq Stock Market (“Nasdaq”) of its intent to delist the Company’s common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the “SEC”) relating to the voluntary... Read More

CYT-0851 demonstrated activity in combination with capecitabine in heavily pretreated platinum-refractory or -resistant ovarian cancer patients with a generally well tolerated safety profile Overall disease control rate was 91% in the capecitabine combination with a median progression-free survival of 170 days LEXINGTON, Mass. / Oct 12, 2023 / Business Wire / Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today presented... Read More

LEXINGTON, Mass. / Jun 30, 2023 / Business Wire / Cyteir Therapeutics, Inc. (“Cyteir” or the “Company”) (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir’s Board of Directors has determined, after consideration of potential strategic alternatives, it is in the best interests of its shareholders to dissolve Cyteir,... Read More

CYT-0851 has demonstrated early activity in combination with capecitabine or gemcitabine in advanced solid tumors and a generally well tolerated safety profile in a heavily pretreated population of patients Overall disease control rate was 71.4% with the capecitabine combination and 87.5% with the gemcitabine combination Enrollment in the Phase 1 dose escalation study continues with preliminary data expected in mid-2023... Read More

Enrollment continuing in trials with CYT-0851 in combination with capecitabine or gemcitabine with data expected in mid-2023 Ended first quarter of 2023 with approximately $137.2 million in cash LEXINGTON, Mass. / May 10, 2023 / Business Wire / Cyteir Therapeutics , Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31, 2023 and provided an... Read More

Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 LEXINGTON, Mass. / Mar 23, 2023 / Business Wire / Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results... Read More

LEXINGTON, Mass. / Feb 06, 2023 / Business Wire / Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department, to oversee the company’s overall financial operations, and to help drive the long-term... Read More

Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash runway into 2026 Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced the strategic prioritization of clinical development of... Read More